Clinical Trial: Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy

U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07130617) titled 'Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy' on Aug. 12.

Brief Summary: To evaluate the efficacy of Megestrol Acetate Oral Suspension in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy in Malignant Solid Tumor Patients

Study Start Date: Sept. 29

Study Type: INTERVENTIONAL

Condition: Efficacy Safety Megestrol Acetate Adult Subject

Intervention: DRUG: Low dose of Megestrol Acetate Oral Suspension combined with standard therapy

A single dose of 312.5 mg/day, administered once daily (QD) for 7 consecutive days.

DRU...